CARsgen Therapeutics to Raise $400 Million in Hong Kong IPO

Shanghai CARsgen Therapeutics is staging an IPO on the Hong Kong Exchange that could raise $400 million to support development of the company's CAR-T portfolio. The shares are scheduled to begin trading on June 18. Lilly Asia Ventures and New China Life are among nine cornerstone investors that will acquire $230 million of the shares. CARsgen is advancing 11 candidates for solid tumors and hematological malignancies including six clinical stage molecules. The company's lead drug is a BCMA CAR-T for multiple myeloma currently in a pivotal Phase II/III trial. More details.... Share this with colleagues: // //